文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

New Pharmacotherapies in Chronic Lymphocytic Leukemia.

作者信息

Olin Jacqueline L, Canupp Katherine, Smith Morgan B

出版信息

P T. 2017 Feb;42(2):106-115.

DOI:
PMID:28163556
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5265236/
Abstract

The authors present the clinical outcomes and therapeutic application of newly approved pharmacotherapies for chronic lymphocytic leukemia and highlight emerging investigational therapeutic options.

摘要

相似文献

[1]
New Pharmacotherapies in Chronic Lymphocytic Leukemia.

P T. 2017-2

[2]
Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia.

Int J Appl Basic Med Res. 2015

[3]
[Small Molecules in the Treatment of Chronic Lymphocytic Leukemia in 2015 and in the Near Future].

Klin Onkol. 2015

[4]
[Therapeutic Options for "Slow go" Patients with Chronic Lymphocytic Leukemia].

Klin Onkol. 2015

[5]
Chronic lymphocytic leukemia and hairy-cell leukemia.

Curr Opin Hematol. 1994-7

[6]
Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options.

Cancer. 2019-2-26

[7]
Emerging therapeutic options for B-cell disorders: idiopathic thrombocytopenic purpura and chronic lymphocytic leukemia.

Clin J Oncol Nurs. 2007-2

[8]
Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.

Expert Rev Hematol. 2016-12-26

[9]
Magic pills: new oral drugs to treat chronic lymphocytic leukemia.

Expert Opin Pharmacother. 2017-3

[10]
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Haematologica. 2018-6-7

引用本文的文献

[1]
Patient-Reported Communication With Their Health Care Team About New Treatment Options for Chronic Lymphocytic Leukemia.

J Patient Exp. 2021-8-25

本文引用的文献

[1]
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.

Leuk Lymphoma. 2017-5

[2]
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.

Leuk Res. 2016-8

[3]
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

Blood. 2016-7-14

[4]
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

Lancet Oncol. 2016-5-20

[5]
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Lancet Oncol. 2016-5-10

[6]
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.

Leuk Lymphoma. 2016

[7]
Cancer statistics, 2016.

CA Cancer J Clin. 2016-1-7

[8]
Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature.

Pharmacoeconomics. 2016-5

[9]
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.

Clin Cancer Res. 2016-5-15

[10]
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.

Eur J Haematol. 2016-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索